Functional and Metabolic Magnetic Resonance Imaging and Positron Emission Tomography for Tumor Volume Definition in High-Grade Gliomas

Seminars in Radiation Oncology

Volumn 19, Issue 3, 2009, Pages 155-162

  Tsien, Christina I ^a   Cao, Yue ^b   Lawrence, Theodore S ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE F 18; BEVACIZUMAB; FLUORODEOXYGLUCOSE F 18; GADOLINIUM; GADOLINIUM PENTETATE; IRINOTECAN; METHIONINE C 11; O (2) FLUOROETHYL TYROSINE F 18; TRACER; UNCLASSIFIED DRUG;

ASTROCYTOMA; BRAIN BLOOD FLOW; BRAIN BLOOD VOLUME; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RISK; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GLIOMA; HUMAN; IMAGE ENHANCEMENT; METABOLIC MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSURGERY; REVIEW; TUMOR RECURRENCE; TUMOR VOLUME;

BRAIN NEOPLASMS; CAPILLARY PERMEABILITY; CEREBROVASCULAR CIRCULATION; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED; TUMOR BURDEN;

EID: 65649122677     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semradonc.2009.02.002     Document Type: Review

References (61)

1. Wallner K.E., Galicich J.H., Krol G., et al. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 16 (1989) 1405-1409
2. Chan J.L., Lee S.W., Fraass B.A., et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J Clin Oncol 20 (2002) 1635-1642
3. Lee S.W., Fraass B.A., Marsh L.H., et al. Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: A quantitative dosimetric study. Int J Radiat Oncol Biol Phys 43 (1999) 79-88
4. Tsien C., Moughan J., Michalski J.M., et al. phase I three-dimensional conformal radiation dose escalation study in newly diagnosed glioblastoma: Radiation Therapy Oncology Group trial 98-03. Int J Radiat Oncol Biol Phys 73 3 (2009) 699-708
5. Intensity Modulated Radiation Therapy Collaborative Working Group. Intensity-modulated radiotherapy: current status and issues of interest. Int J Radiat Oncol Biol Phys 51 (2001) 880-914
6. Narayana A., Yamada J., Berry S., et al. Intensity-modulated radiotherapy in high-grade gliomas: Clinical and dosimetric results. Int J Radiat Oncol Biol Phys 64 (2006) 892-897
7. Thornton Jr. A.F., Hegarty T.J., Ten H.R.K., et al. Three dimensional treatment planning of astrocytomas: A dosimetry study of cerebral irradiation. Int J Radiat Oncol Biol Phys 20 (1991) 1309-1315
8. Nelson S.J., Graves E., Pirzkall A., et al. In vivo molecular imaging for planning radiation therapy of gliomas: An application of 1H MRSI. J Magn Reson Imaging 16 (2002) 464-476
9. Zakian K.L., Koutcher J.A., Ballon D., et al. Developments in nuclear magnetic resonance imaging and spectroscopy: Application to radiation oncology. Semin Radiat Oncol 11 (2001) 3-15
10. Pardo F., Aronen H., Kennedy D., et al. Functional cerebral imaging in the evaluation and radiotherapeutic treatment planning of patients with malignant glioma. Int J Radiat Oncol Biol Phys 30 (1994) 663-669
11. Grosu A.L., Feldmann H., Dick S., et al. Implications of IMT-SPECT for postoperative radiotherapy planning in patients with gliomas. Int J Radiat Oncol Biol Phys 54 (2002) 842-854
12. Grosu A.L., Weber W.A., Franz M., et al. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 63 (2005) 511-519
13. Meyer C.R., Boes J.L., Kim B., et al. Demonstration of accuracy and clinical versatility of mutual information for automatic multimodality image fusion using affine and thin-plate spline warped geometric deformations. Med Image Anal 1 (1997) 195-206
14. Petti P.L., Kessler M.L., Fleming T., et al. An automated image-registration technique based on multiple structure matching. Med Phys 21 (1994) 1419-1426
15. Herholz K., Pietrzyk U., Voges J., et al. Correlation of glucose consumption and tumor cell density in astrocytomas. A stereotactic PET study. J Neurosurg 79 (1993) 853-858
16. Grosu A.L., Wiedenmann N., and Molls M. Biological imaging in radiation oncology. Z Med Phys 15 (2005) 141-145
17. Jager P.L., Vaalburg W., Pruim J., et al. Radiolabeled amino acids: Basic aspects and clinical applications in oncology. J Nucl Med 42 (2001) 432-445
18. Grosu A.L., Weber W.A., Riedel E., et al. L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. Int J Radiat Oncol Biol Phys 63 (2005) 64-74
19. Langen K.J., Muhlensiepen H., Holschbach M., et al. Transport mechanisms of 3-[123I]iodo-alpha-methyl-L-tyrosine in a human glioma cell line: Comparison with [3H]methyl]-L-methionine. J Nucl Med 41 (2000) 1250-1255
20. Torii K., Tsuyuguchi N., Kawabe J., et al. Correlation of amino acid uptake using methionine PET and histological classifications in various gliomas. Ann Nucl Med 19 (2005) 677-683
21. Sato N., Suzuki M., Kuwata N., et al. Evaluation of the malignancy of glioma using 11C-methionine positron emission tomography and proliferating cell nuclear antigen staining. Neurosurg Rev 22 (1999) 210-214
22. Kracht L.W., Friese M., Herholz K., et al. Methyl-[11C]-L-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma. Eur J Nucl Med Mol Imaging 30 (2003) 868-873
23. Rasey J.S., Grierson J.R., Wiens L.W., et al. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 43 (2002) 1210-1217
24. Shields A.F., Grierson J.R., Dohmen B.M., et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4 (1998) 1334-1336
25. Nuutinen J., Sonninen P., Lehikoinen P., et al. Radiotherapy treatment planning and long-term follow-up with [(11)C]methionine PET in patients with low-grade astrocytoma. Int J Radiat Oncol Biol Phys 48 (2000) 43-52
26. Lee I.H., Piert M., Gomez-Hassan D., et al. Association of (11)C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys 73 2 (2009) 479-485
27. Popperl G., Kreth F.W., Herms J., et al. Analysis of 18F-fet PET for grading of recurrent gliomas: Is evaluation of uptake kinetics superior to standard methods?. J Nucl Med 47 (2006) 393-403
28. Chen W., Delaloye S., Silverman D.H., et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: A pilot study. J Clin Oncol 25 (2007) 4714-4721
29. Cao Y., Sundgren P.C., Tsien C.I., et al. Physiologic and metabolic magnetic resonance imaging in gliomas. J Clin Oncol 24 (2006) 1228-1235
30. Nelson S.J. Multivoxel magnetic resonance spectroscopy of brain tumors. Mol Cancer Ther 2 (2003) 497-507
31. Preul M.C., Caramanos Z., Collins D.L., et al. Accurate, noninvasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy. Nat Med 2 (1996) 323-325
32. Li X., Lu Y., Pirzkall A., et al. Analysis of the spatial characteristics of metabolic abnormalities in newly diagnosed glioma patients. J Magn Reson Imaging 16 (2002) 229-237
33. Vigneron D., Bollen A., McDermott M., et al. Three-dimensional magnetic resonance spectroscopic imaging of histologically confirmed brain tumors. Magn Reson Imaging 19 (2001) 89-101
34. Pirzkall A., Li X., Oh J., et al. 3D MRSI for resected high-grade gliomas before RT: Tumor extent according to metabolic activity in relation to MRI. Int J Radiat Oncol Biol Phys 59 (2004) 126-137
35. McKnight T.R., von dem Bussche M.H., Vigneron D.B., et al. Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence. J Neurosurg 97 (2002) 794-802
36. Park I., Tamai G., Lee M.C., et al. Patterns of recurrence analysis in newly diagnosed glioblastoma multiforme after three-dimensional conformal radiation therapy with respect to pre-radiation therapy magnetic resonance spectroscopic findings. Int J Radiat Oncol Biol Phys 69 (2007) 381-389
37. Pirzkall A., McKnight T.R., Graves E.E., et al. MR-spectroscopy guided target delineation for high-grade gliomas. Int J Radiat Oncol Biol Phys 50 (2001) 915-928
38. Graves E.E., Nelson S.J., Vigneron D.B., et al. Serial proton MR spectroscopic imaging of recurrent malignant gliomas after gamma knife radiosurgery. AJNR Am J Neuroradiol 22 (2001) 613-624
39. Chan A.A., Lau A., Pirzkall A., et al. Proton magnetic resonance spectroscopy imaging in the evaluation of patients undergoing gamma knife surgery for grade IV glioma. J Neurosurg 101 (2004) 467-475
40. Rosen B.R., Belliveau J.W., Aronen H.J., et al. Susceptibility contrast imaging of cerebral blood volume: human experience. Magn Reson Med 22 (1991) 293-299
41. Tofts P.S., Brix G., Buckley D.L., et al. Estimating kinetic parameters from dynamic contrast-enhanced T, vol 1- weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10 (1999) 223-232
42. Rempp K.A., Brix G., Wenz F., et al. Quantification of regional cerebral blood flow and volume with dynamic susceptibility contrast-enhanced MR imaging. Radiology 193 (1994) 637-641
43. Cao Y., Shen Z., Chenevert T.L., et al. An estimate of vascular permeability and cerebral blood volume using Gd-DTPA contrast enhancement and dynamic T2* weighted MRI. J Magn Reson Imaging 24 2 (2006) 288-296
44. Johnson G., Wetzel S.G., Cha S., et al. Measuring blood volume and vascular transfer constant from dynamic, T(2)*-weighted contrast-enhanced MRI. Magn Reson Med 51 (2004) 961-968
45. Cao Y., Nagesh V., Hamstra D., et al. The extent and severity of vascular leakage as evidence of tumor aggressiveness in high-grade gliomas. Cancer Res 66 (2006) 8912-8917
46. Aronen H.J., Gazit I.E., Louis D.N., et al. Cerebral blood volume maps of gliomas: Comparison with tumor grade and histologic findings. Radiology 191 (1994) 41-51
47. Knopp E.A., Cha S., Johnson G., et al. Glial neoplasms: Dynamic contrast-enhanced T2*-weighted MR imaging. Radiology 211 (1999) 791-798
48. Sugahara T., Korogi Y., Kochi M., et al. Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. AJR Am J Roentgenol 171 (1998) 1479-1486
49. Donahue K.M., Krouwer H.G., Rand S.D., et al. Utility of simultaneously acquired gradient-echo and spin-echo cerebral blood volume and morphology maps in brain tumor patients. Magn Reson Med 43 (2000) 845-853
50. Kremer S., Grand S., Remy C., et al. Cerebral blood volume mapping by MR imaging in the initial evaluation of brain tumors. J Neuroradiol 29 (2002) 105-113
51. Aronen H.J., Pardo F.S., Kennedy D.N., et al. High microvascular blood volume is associated with high glucose uptake and tumor angiogenesis in human gliomas. Clin Cancer Res 6 (2000) 2189-2200
52. Roberts H.C., Roberts T.P., Brasch R.C., et al. Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: Correlation with histologic grade. AJNR Am J Neuroradiol 21 (2000) 891-899
53. Provenzale J.M., Wang G.R., Brenner T., et al. Comparison of permeability in high-grade and low-grade brain tumors using dynamic susceptibility contrast MR imaging. AJR Am J Roentgenol 178 (2002) 711-716
54. Law M., Yang S., Babb J.S., et al. Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol 25 (2004) 746-755
55. Law M., Young R.J., Babb J.S., et al. Gliomas: Predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 247 (2008) 490-498
56. Cao Y., Tsien C.I., Nagesh V., et al. Clinical investigation survival prediction in high-grade gliomas by MRI perfusion before and during early stage of RT. Int J Radiat Oncol Biol Phys 64 (2006) 876-885
57. Sadeghi N., Salmon I., Tang B.N., et al. Correlation between dynamic susceptibility contrast perfusion MRI and methionine metabolism in brain gliomas: Preliminary results. J Magn Reson Imaging 24 (2006) 989-994
58. Moffat B.A., Chenevert T.L., Lawrence T.S., et al. Functional diffusion map: A noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A 102 (2005) 5524-5529
59. Chenevert T.L., Stegman L.D., Taylor J.M., et al. Diffusion magnetic resonance imaging: An early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 92 24 (2000) 2029-2036
60. Hamstra D.A., Galban C.J., Meyer C.R., et al. Functional diffusion map as an early imaging biomarker for high-grade glioma: Correlation with conventional radiologic response and overall survival. J Clin Oncol 26 (2008) 3387-3394
61. Moffat B.A., Chenevert T.L., Lawrence T.S., et al. Physiologic diffusion map: A noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A 102 (2005) 5524-5529